Eric Venker, President & Immunovant Chief Executive Officer, on May 20, 2026, sold 200,000 shares in Roivant Sciences (ROIV) for $6,054,000. Following the Form 4 filing with the SEC, Venker has control over a total of 1,613,063 common shares of the company, with 1,613,063 shares held directly.
SEC Filing: